Praxis Precision Medicines, Inc. announced an exclusive collaboration and license agreement with Tenacia Biotechnology (Shanghai) Company Ltd. Under the agreement, Tenacia will develop and commercialize ulixacaltamide for the treatment of essential tremor in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. As part of the collaboration agreement, Praxis will receive $15 million up front, including $5 million in cash and a $10 million investment in Praxis common stock. Additionally, Praxis will be eligible for an additional $264 million in development, regulatory and commercialization milestone payments, as well as tiered royalties on net sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
54.8 USD | +3.63% | +16.87% | +145.96% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+145.96% | 907M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- PRAX Stock
- News Praxis Precision Medicines, Inc.
- Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China